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ABSTRACT 
 Selenium is a required micronutrient in mammalian cells.  It is incorporated in the 
form of selenocysteine into selenoenzymes such as glutathione peroxidase and 
thioredoxin reductase, and is absolutely required for activity.  Thioredoxin reductase is 
necessary for reduction of oxidized thioredoxin and therefore plays a major role in 
maintaining the redox status of the cell. Glutathione peroxidase is responsible for 
reducing peroxides into their corresponding alcohols and water.  Together, these 
selenoenzymes constitute a significant part of the cell’s arsenal to defend itself against 
oxidative stress. Exogenous sources of oxidative stress, such as UV radiation, are capable 
of generating reactive oxygen species (ROS).   Elevated levels of ROS can lead to 
covalent modifications of lipids, nucleic acids, and proteins within a cell.  This damage 
has been implicated in the development of cancer and degenerative diseases. As the skin 
is the first level of defense for UV radiation, skin cancer is an obvious concern.  
 Previous studies have demonstrated a protective effect against UV-induced 
cytotoxicity when selenium compounds were administered to skin cells in cell culture 
models.  Topical selenium application to mice has also been shown to reduce UV damage 
to skin. Although a variety of chemical forms of selenium are available in nutritional 
supplements, the efficiency by which they are used for selenoprotein synthesis varies 
greatly. It is debated within the selenium research community which form is best for use 
as a supplement.  In this study, we have focused on a selenotrisulfide derivative of alpha-
lipoic acid (LASe). We have examined its utilization for selenoprotein synthesis through 
radiolabeling studies (75Se) in a human keratinocyte cell line (HaCaT).  We have 
determined that is incorporated into selenoproteins with nearly the same efficiency as 
selenite and L-selenocysteine. We have also determined that LASe is far more efficient as 
a supplement in cell culture than selenate or L-selenomethionine, two forms of selenium 
commonly used as supplements.  LASe was also found to protect HaCaT keratinocytes 
from UV- induced cytotoxicity. Cells pretreated with LASe and exposed to 500J/m2 and 
750J/m2 of broadband (UVA/UVB) UV radiation showed greater survival than untreated 
controls in a dose –dependent manner.  Cells pre-treated either with lipoic acid or 
selenium in the form of selenite alone also observed protection. Nonetheless, these 
finding are significant given that LASe was previously shown to penetrate the skin better 
than other forms of selenium. These results indicate that LASe has the potential for use as 
a topical antioxidant upon further testing in animal studies. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
       
  
 Selenium is a trace mineral which has chemical properties similar to sulfur(1). 
Selenium has been shown to be required for optimal health in mammals.  This has been 
known since Klaus Schwarz and Milton Scott discovered the harmful effects of selenium 
deficiency in farm animals in the 1950’s, and how these effects could be ameliorated with 
selenium supplementation (2).  It is now known that selenium is utilized in the diet for 
the synthesis of selenoenzymes. Each of these selenoenzymes contains selenocysteine at 
their active site, and is required for activity (3). The mechanism of the synthesis of 
bacterial selenoproteins is well understood, using Escherichia coli as a model (4). 
Synthesis of selenoproteins in eukaryotes, although not as well defined,  is  increasingly 
understood (5).    
 
 
Figure 1 
Selenocysteine insertion to selenoproteins.  Picture (a) represents prokaryotic insertion 
and picture (b) represents eukaryotic insertion (5).  
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Selenocysteine is cotranslationally inserted at a UGA codon (usually a stop codon) by a 
selenocysteyl tRNA [ser] sec in the presence of specific elongation factors. Selenophosphate 
synthetase converts selenide to selenophosphate, which is the selenium donor responsible 
for converting a serine charged tRNA to selenocysteyl-tRNA.  Stem-loop structures 
within the mRNA of selenoproteins, called selenocysteine insertion sequences (SECIS 
elements) are required for selenoprotein synthesis (5). 
In the 1970’s, selenium was shown to be a component of the bovine form of the 
antioxidant enzyme glutathione peroxidase, which is responsible for detoxifying 
peroxides (6). It was much later (1995) determined that selenium is a necessary 
component of the enzyme thioredoxin reductase, which is responsible for reducing 
thioredoxin (7) (8). Based on in silico analysis of the human genome, it is estimated that 
about 25 mammalian selenoproteins exist (9). A great deal of progress has been made in 
the selenium field regarding selenium deficiency and supplementation in humans.  It is 
now known that severe deficiency of this mineral can lead to serious health problems, 
and that less severe deficiency  also results in a number of adverse effects in humans 
(10).  Consequently, the significance of research in this area is evident.   
 Lack of adequate selenium in the diet can lead to a number of adverse health 
conditions, and there are varying degrees to which a human’s health may be 
compromised by inadequate selenium. One of the most severe conditions associated with 
selenium deficiency is Keshan disease. Keshan disease is a condition which is limited to 
individuals living in certain geographic areas of China in which the selenium levels in the 
soil are very low. The disease is classified as a cardiomyopathy, and is associated with 
infection by a cocksackie virus.  It is known that selenium deficiency makes individuals 
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more susceptible to this virus, which is a causative agent of myocarditis (inflammatory 
heart disease).  Furthermore, selenium deficiency in an infected individual results in a 
mutation to the virus itself, which has been shown to increase its virulence.  Kashin-Beck 
disease is an arthritic condition associated with both selenium and iodine deficiency.  The 
condition is characterized by enlarged joints and distorted growth of long bones. Kashin-
Beck disease is also isolated to regions with low soil selenium (10).   
Less severe selenium deficiency has also been linked to a number of health 
problems.  Lower than adequate plasma selenium levels have been associated with 
increased susceptibility to viral infection, Alzheimer’s disease, decreased viable sperm 
count in men, and increased incidence of death due to cardiovascular disease (11).  It has 
been assumed that the primary effects of selenium deficiency result from a decrease in 
the antioxidant action of enzymes that contain selenium, such as glutathione peroxidase 
and thioredoxin reductase, but until all selenoproteins are identified and characterized this 
remains speculative. 
 There is a great deal of epidemiological data that suggests deficiency in 
selenium leads to increased risk of cancer. In the late 1960’s it was determined that in the 
United States an inverse relationship exists between cancer deaths and the amount of 
selenium in crops within certain areas (12).  A study published in 1971 reported that 
individuals living in areas with average or higher than average concentrations of selenium 
in the crops had a lower death rate from cancer of the gastrointestinal tract, lung and 
breast than those in low selenium areas (13).  This inverse relationship was also found in 
a study examining the death rate due to colorectal cancer. Furthermore, it has been shown 
that the selenium status of individuals with cancer tends to be lower than that of healthy 
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controls (14).  In a study involving the eventual development of non-melanoma skin 
cancer and the development of adenomatus polyps of the colon, the individuals with 
lower plasma selenium levels had a higher incidence of these cancers (15).  Likewise, a 
Finnish study found that selenium in the serum was lower in individuals with cancer than 
in the healthy control individuals (16).  
 In addition to epidemiologic studies of deficiency in selenium status, significant 
effort in clinical research studies has focused on selenium supplementation. Due to the 
strong correlation between less than adequate selenium status and higher incidence of 
cancer, it seems logical that additional supplementation of selenium in the diet of 
individuals afflicted with such conditions would help to reduce the risk of cancer. It is 
from this line of reasoning that a number of studies involving the effect of selenium 
supplementation have arisen.  In particular the Nutritional Prevention of Cancer (NPC) 
Trial, involving individuals with a history of basal or squamous cell carcinoma, 
demonstrated that selenium supplementation was efficient in reducing the incidence of 
lung, colon and prostate cancers by about 50% (17).  Though the study was conducted in 
order to evaluate the use of selenium supplements in patients with a history of skin 
cancer, the results obtained did not show any effect of selenium supplementation on 
recurrence of skin cancer.  The fact that there was a reduced incidence of other types of 
cancer in individuals who received selenium supplements (200 µg per day as selenized 
yeast) compared to those who received a placebo is strong evidence supporting the ability 
of selenium to reduce cancer risk.  The individuals in this study who received the greatest 
benefit from selenium supplementation were those whose plasma selenium levels were 
the lowest.  Individuals with the highest plasma selenium levels did not experience a 
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reduced incidence of cancer upon supplementation with selenium.  Taken together, these 
results suggest that selenium supplementation is most effective in reducing cancer 
incidence in individuals with selenium deficiency.   
 Perhaps the largest clinical trial involving the supplementation of selenium and 
cancer is the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (18).  The 
SELECT trial is a subtrial begun from initial data elucidated in the NPC trial. SELECT is 
a clinical trial that examines the incidence of prostate cancer in individuals supplemented 
with both vitamin E and selenium. The effect of supplementation with selenium (in the 
form of selenomethionine) and Vitamin E alone as well as together will be examined 
against the effect of each supplement alone as well as compared to controls (19). Though 
it will not be complete until 2013, the evidence already available suggests that the two 
supplements are effective at preventing prostate cancer (18) .  
 It is clear that a great deal of evidence exists to support the idea that selenium is 
effective at reducing certain types of cancer.  It is generally agreed upon that selenium’s 
effect on cancer is due to its antioxidant properties (i.e. increasing the levels of 
thioredoxin reductase and glutathione peroxidase).  Oxidative damage results in 
modification of cellular proteins, lipids, and DNA, and it is thought that excess 
modification of this kind leads to many of the diseases associated with aging, including 
cancer (20).    There are a number of sources of reactive oxygen species such as 
superoxides, hydrogen peroxides and hydroxyl radicals. Oxidative stress may come from 
an endogenous source, such as the normal metabolic processes within a cell, but 
exogenous sources of oxidative stress also exist.  One exogenous source of oxidative 
stress is the sun, specifically, the ultraviolet radiation it emits.  Concern of skin cancer 
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risk is growing as the ozone layer is increasingly depleted (21).  The ozone absorbs most 
UVC rays (200-280nm), but we are left susceptible to UVA and UVB rays. Most of the 
UV rays responsible for damage to skin are in the UVA (320-400nm) and UVB (290-
320nm) range. It is known that UVB radiation causes direct damage to DNA, while UVA 
radiation generates reactive oxygen species (22).  
Though the NPC trial showed that oral selenium supplementation did not 
significantly reduce the risk of recurrent skin cancer, there is evidence that topical 
selenium supplementation can help to protect from skin cancer.  Several studies involving 
topical application of selenium to animals as well as the addition of selenium compounds 
to skin cells in culture have shown selenium supplementation to be protective. A study by 
Burke (23) has shown that topical selenomethionine, combined with vitamin E, reduced 
the incidence of skin damage due to blistering and inflammation in a mouse model 
(hairless mice) treated with UV. In addition, a number of cell culture studies have 
demonstrated that selenium is protective from UV-induced cell death.  Selenite and 
selenomethionine pretreatment of human melanocytes and keratinocytes  reduced UVB 
induced death (24) (25).  Furthermore,  selenite and selenomethionine  have shown 
protection from UV induced apoptosis of human primary keratinocytes (26).  
 Even though there are certainly advantages to selenium supplementation, 
certain forms of selenium can also prove to be toxic. Selenium toxicity, or selenosis, has 
been observed in animals as well as humans, but was first identified in farm animals 
(horses and cattle in the 1930’s in South Dakota). These animals had conditions called 
“blind staggers” and “alkali disease” (27).   Alkali disease is a less chronic poisoning than 
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blind staggers, but both are the result of animals consuming plants which are known to 
accumulate high levels of selenium.  
 Toxicity in humans is rare, but can occur. Because there are several chemical 
forms of selenium, and each is metabolized differently, it is necessary to determine the 
potential toxicity of a selenium compound used as a supplement.  The most toxic form of 
selenium in selenite. Selenite is reduced to selenide and then incorporated into 
selenoenzymes (28) (3) (5).  Selenocysteine is an efficient nutritional source of selenium, 
but is not used in supplements due to the high cost of chemical synthesis. Less toxic 
forms of selenium, such as selenomethionine and selenate exist, though they are less 
efficient at selenoenzyme synthesis. Additionally, selenomethionine has the ability to be 
incorporated non-specifically into methionine residues of proteins (29).  Such non-
specific incorporation could cause changes to a protein’s structure, and consequently, its 
function.  Long-term supplementation in cell culture models or animal studies with L-
selenomethionine has yet to be carried out. 
 Selenocysteine protein synthesis requires that selenite is reduced to selenide, 
selenide being the selenium donor for selenophosphate synthetase (5).  It is believed that 
glutathione, a small cysteine containing peptide, is involved in this reduction process in 
vivo. Glutathione has been shown to react with selenite to form a selenotrisulfide in 
which selenium is substituted for sulfur (30). This spontaneous chemical reaction was 
initially described by Painter, which requires a sulfur to selenium ratio of 4:1 (28) .  The 
formation of selenotrisulfides was also examined by Ganther.  Glutathione-based 
selenotrisulfides are not stable at physiological pH (30) . Selenotrisulfides are 
intermediates which are formed in the reduction of selenite to selenide. Consequently, 
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selenotrisulfides are further in the metabolic pathway to selenoenzyme synthesis than 
other forms of selenium. 
Due to the protection that selenium provides against UV induced oxidative 
damage, as well as the close relationship between selenium’s toxicity and its utilization in 
selenoenzyme synthesis, it is clear that a need exists for an efficiently utilized, non-toxic 
selenium compound. In addition to the ability of such a compound to be utilized for 
selenoprotein synthesis, an ideal compound would be absorbed into the skin, as an oral 
supplement is not the most effective.  In 2000, a unique selenotrisulfide derivative of 
alpha-lipoic acid was  initially characterized and is shown in figure 2 (31). This 
compound (LASe) was formed by the same spontaneous reaction  previously described 
by Painter  and Ganther  (28) (32).  Unlike other known selenotrisulfides, this lipoic acid 
derivative of a selenotrisulfide has been shown to be stable at physiological pH  (31). 
Furthermore, due to its hydrophobic lipoic acid component, LASe has the potential to 
penetrate hydrophobic barriers, such as human skin. Furthermore,  the established 
antioxidant properties of lipoic acid  make this compound an excellent potential topical 
antioxidant  (33) (34).   In this study, we have examined the capacity of the selenium 
derived from LASe to be utilized by cells in culture for selenoenzyme synthesis and 
determined whether this compound has the ability to protect cells from UV induced 
cytotoxicity. 
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Figure 2 
The chemical structure of LASe (31) 
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CHAPTER 2: MATERIALS AND METHODS 
 
Synthesis and Purification of LASe 
 The Painter reaction for synthesis of the LASe was carried out as previously 
described (31), with modifications.  The reaction was carried out by combining two 
solutions:  a 50 mL solution of 4 mM dihydrolipoic acid (DHLA) made in 100% ethanol 
and a 50mL solution of 2 mM sodium selenite (Na2SeO3) in water. Upon mixing the 
solution thus contains a 2:1 ratio of DHLA: Na2SeO3  in 50% ethanol. This 2:1 DHLA: 
Na2SeO3 results in a 4:1 ratio of sulfur to selenium. The reaction mixture was kept at 
room temperature for 30 minutes to allow the reaction to go to completion. 
The entire reaction mixture was loaded in 5 mL increments using a 5 mL loading 
loop (Rheodyne) onto a preparative C18 high pressure liquid chromatography (HPLC) 
column (Vydac) to which it bound. The column was washed for 25 minutes at a flow rate 
of 2 mL/minute with dH2O-TFA solvent to allow the compound (LASe) to adsorb to the 
column.  The LASe was then eluted using a linear gradient of methanol -TFA (0.1%) for 
30 minutes at a flow rate of 2 mL/minute.  The UV-visible spectrum of the fractions 
(analyzed using a Hewlett-Packard 8453 spectrophotometer) eluted in the range where 
LASe was expected to elute from the column, based on previous studies(31) .   Fractions 
were pooled and the column and lines were washed with dH2O, pH 2.0. The pooled 
fractions were again loaded onto the preparative C18 column.  The column was washed 
with dH2O (pH 2.0) to ensure binding of LASe.  An ethanol gradient was used (0%-
100%) to elute the compound.  Fractions containing LASe were pooled, based on their 
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absorbance in the correct region (288 nm).    The sample was then stored at -20°C until 
use.  
 
Cell Culture Methods 
Hela S3 cultivation.  HeLa S3 cells, obtained from the laboratory of T.C. 
Stadtman (NHLBI, NIH) were cultured in sterile, gamma irradiated, tissue culture treated 
12- well plates (growth surface 3.66 cm² per well) or screw cap flasks with venting 
position (growth surface 25 cm²). Tissue culture plates and flasks were purchased from 
Techno Plastic Products (TPP).  Cells were cultivated in Dulbecco’s Modification of 
Eagle’s Medium (DMEM) containing 4.5 g/L- glucose, L-glutamine (Cellgro) with 10% 
fetal calf serum (FCS) (ICN Biomedicals), 100 units/mL penicillin and 100 µg/mL 
streptomycin (Cellgro) at 37 ºC in a humidified 5% CO2   atmosphere (Revco Elite II 
incubator).  Five milliliters (mL) of cell culture medium (DMEM) was used in 25 cm² 
flasks and 2 mL was used in 12-well plates.  To maintain cells for continuous culture, 
cells were harvested and re-plated when they reached confluence. Culture medium was 
exchanged every 2-3 days.  
To harvest HeLa cells, culture medium was removed and replaced with enough 
Trypsin-EDTA (Cellgro) to cover the cells (2 mL in the 25 cm² and 0.5 mL in 12-well 
dishes). Cells were incubated at 37 degrees for 5-10 minutes, or until cells were visibly 
detached from growth surface when viewed under an inverted microscope.  Cells in 
trypsin were transferred to a sterile centrifuge tube, and DMEM was added to inhibit 
further action by trypsin. Cells were pelleted by centrifugation for 2 minutes at 1, 000 
rpm (Hermle Labnet Z383K).  Medium was then decanted and the cell pellet was 
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resuspended in DMEM.  The cells were again harvested by centrifugation for 2 minutes 
at 1, 000 rpm. DMEM was decanted, and cells were resuspended again in culture medium 
if they were being plated, or in phosphate buffered saline (PBS) with calcium and 
magnesium (Cellgro) if they were to be used for further analyses such as SDS-PAGE, 
immunoblot, or radioisotope analysis.  
HaCaT cultivation.  Spontaneously transformed HaCaT keratinocytes (gift of 
Dr. Norbert Fusenig ) were cultured in 25cm² flasks in 5 mL of DMEM containing  4.5 
g/L glucose, L-Glutamine, 10% FCS, 100 units/mL penicillin and 100 µg/mL 
streptomycin at 37 ºC in a  humidified 5% CO2    atmosphere (Revco Elite II incubator). 
To maintain cells for continuous culture, cells were harvested and re-plated 5 days after 
reaching confluence, at no higher than 1 to 5 ratio.  Culture medium was exchanged at 
least every 2-3 days. 
 To harvest HaCaT cells, culture medium was removed and cells were covered 
with a 0.05% ethylenediaminetetraacetic acid (EDTA) solution made in PBS without 
calcium and magnesium. Cells were incubated at 37°C for 15-20 minutes to allow the 
EDTA solution to disintegrate the desmosomes present in the culture monolayer.  The 
EDTA solution was then removed and the cells were incubated for 5-10 minutes at 37°C 
with Trypsin-versene to allow detachment of cells from the monolayer. DMEM was 
added, and detached cells were harvested by centrifugation for 2 minutes at 1,000 rpm. 
Cells were resuspended in DMEM and again harvested by centrifugation for 2 minutes at 
1,000 rpm. The culture medium was removed, and cells were resuspended in fresh culture 
medium if being plated, or in PBS if being used for analysis of radiolabeled selenium 
incorporation.  
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Assessment of Cell Viability for UV Irradiation Studies 
 For UV irradiation studies HaCaT cells were cultivated in 12-well dishes.  Cell 
viability was assayed using the trypan blue exclusion method (as explained below). The 
number of viable cells was determined by counting of cells using an Improved Neubauer 
hemocytometer (Hausser Scientific).  Cells for UV irradiation were plated to achieve 
approximately 80% confluence.  Cells were initially plated in 1 mL of DMEM, and 24 
hours after plating, medium was exchanged for 2 mL of fresh DMEM. HaCaT cells were 
also grown in 96-well dishes for UV studies when cell proliferation was assayed for by 
MTT (see below). Cells were plated at 5,000 cells per well with 100 µL of DMEM.  
Media was exchanged 24 hours after plating of cells. 
Assessment of Cell Viability Using Trypan Blue.  Trypan blue dye in 0.4% 
phosphate buffered saline solution was purchased from MP Biomedicals. The dye was 
used to stain cells for visualization under an inverted microscope (Nikon) using the 20X 
objective lens.  The cells were viewed on an Improved Neubauer hemocytometer 
(Hausser Scientific). Cells were counted using a cell counter (Fisher). To prepare cells for 
counting, cells were harvested as previously described, and resuspended in PBS with 
calcium and magnesium. This cell suspension was mixed with 100% trypan blue dye at a 
1:1 ratio.  The number of live (not absorbing dye) and dead cells were counted on each 
side of the hemocytometer was recorded.  Both sides of the hemocytometer were 
counted, and these two numbers were averaged.  The number of cells per mL of culture 
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were determined using the manufacturer’s instructions for the hemocytometer (Hausser 
Scientific). 
 Assessment of Cell Viability Using MTT Assay.  MTT reagent was purchased 
from Midwest Scientific.  A working solution of 5mg/mL was made in PBS and filter 
sterilized. Solutions were stored at 4ºC in the dark, and were kept for no more than 2 
weeks.  Cells were cultivated in 96 well plates  at  a density of 5,000 cells/well in 100µL 
of medium which consisted of 90% DMEM with serum and 10% defined keratinocyte 
medium (DKM).  The protocol used for the assay was adapted from the Molecular Probes 
Vybrant® MTT Cell Proliferation Assay Kit. At the appropriate time point for assessing 
cell viability for each experiment (either 24 or 48 hours), 10µL of the 5mg/mL MTT was 
added to each well.  The plates were then returned to the incubator so that the dye could 
form a precipitate in the presence of metabolically active cells.  The formation of a purple 
formazan precipitate occurred within 2- 4 hours.  After four hours incubation, 100 µL of a 
detergent solution (10% SDS, 10nM HCl) was added to solubilize the precipitated 
crystals.  Following overnight incubation the absorbance at 570nm was determined using 
aa Dynex Technologies Opsys MR microplate reader.  
Figure 3 shows the average absorbance of MTT plotted versus the number of cells 
plated per well, in order to determine the optimum concentration of cells for experiments 
using MTT as a marker.  Determination of optimal cell counts for use in the 96-well 
plates was performed as described in the ATCC® MTT cell proliferation assay 
instructions.  First, HaCaT cells from a confluent 25cm2 flask were harvested and 
resuspended in 1mL of DMEM.  The average number of HaCaT cells in one confluent 
flask was counted by trypan blue dye method (as previously described), and was found to 
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be 5.5 X 106 cells. Consequently, when resuspended in 1 mL of DMEM, the cells are at a 
density of  5.5 X 106 cells/mL.  From this suspension, dilutions were made in DMEM.  
First, a dilution to 1 X 106 cells/mL was made in DMEM.  From this dilution, subsequent 
dilutions were made in DMEM of 500,000cells/mL, 100,000cells/mL, 50,000cells/mL, 
25,000 cells/mL and 10,000 cells/mL.  Next 100µL of each suspension was plated in 
triplicate in a 96-well microplate, so that there was triplicate plating of cells in the 
following amounts; 50,000cells/well, 10,000cells/well, 5,000cells/well, 2,500cells/well, 
and 1,000cells/well.  
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Figure 3 
Calibration of MTT Assay.  Each bar represents at least 3 independent cultures, with the 
standard deviation plotted as error. 
 
  
From these results, it was concluded that plating 5,000 cells per well would yield 
an absorbance reading which is accurate for control (untreated) cells.  When cells were 
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cultured in 24-well plates, a proportionally larger number of cells (48,000 cells/well) was 
used.  When cells were cultivated in 24-well plates, volumes of culture medium, MTT, 
and detergent were increased so that they were proportional to those used in the 96-well 
plate experiments.  Cells were cultured in 1mL of culture media, and 100 µL of MTT was 
added to each well at the time which cell viability was to be assessed.  After overnight 
incubation with SDS-HCl solution, the contents of each well were resuspended and 200 
µL from each well containing solubilized MTT precipitate was transferred to the well of a 
96-well microplate. The absorbance was then read at 570nm on the Dynex microplate 
reader. 
 
Nutritional Utilization Studies 
Treatment with Selenium Compounds and Radiolabeling.  For radiolabeling 
studies, cells were cultivated as a monolayer to approximately 60% confluence. Culture 
medium was removed and replaced with fresh media containing a basal concentration (10 
nM) of unlabeled sodium selenite.  Cells were radiolabeled using equal amounts of 75Se 
(University of Missouri), usually 10µCi.  Selenium compounds were added to cells in 
concentrations ranging from 25nM-1µM.  Sodium selenite, L-selenocysteine , and LASe 
(31)  were added to cells in concentrations ranging from 25 nM-150nM in HeLa cells and 
25nM-200nM in HaCat cells. L-selenomethionine, selenate, and LASe were added to 
cells in concentrations ranging from 250nM- 1µM in HeLa and 200nM-1µM in HaCaT.   
Cells were incubated for 48 hours following these additions and each experiment was 
performed in triplicate for statistical analysis of the data.  
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Protein Concentration Determination.  Protein concentration was determined 
as previously described (35). Concentrated Bradford reagent was purchased from 
BioRad.  One mL of the Bradford reagent was added to a 1.5 mL microcentrifuge tube. 
Either the cell extract itself or a dilution of the cell extract (made in water) was added to 
the 1mL of Bradford reagent. Tubes were vortexed to mix the contents and then allowed 
to sit at room temperature for 10 minutes to allow the coomassie dye to bind to the 
cellular proteins.  After 10 minutes, the contents of each tube were transferred to 
disposable visible cuvettes ( Fisherbrand ), and the absorbance of each sample was read 
at 595nm using a model 8453 Hewlett-Packard spectrophotometer. A standard curve was 
generated using bovine serum albumin (Pierce) for each experiment.  
Measurement of  75Se Present in Cellular Protein Following Radiolabeling. 
Following radiolabeling and treatment with selenium compounds, the cell culture 
medium was removed and cells were harvested, as described above. Cells were 
resuspended in 100 µl of  buffer (50 mM tricine buffer containing 0.1 mM benzamadine, 
0.5 mM EDTA and 1mM dithiothreitol) and lysed by sonication for 5-10 seconds (Fisher 
Scientific model 100).  Protein concentration was determined using the Bradford method.  
The amount of labeled selenoprotein in the cell extract was determined by assaying for 
75Se (Perkin Elmer model 1470) and reported with respect to total protein (cpm/µg).   
Equal amounts of protein (indicated in figure legends) from crude cell extracts 
were applied to 12% polyacrylamide gels, which were made using Bio-Rad casting 
stands and 0.75mm glass plates. Gels were electrophoresed at 150 volts for 55 minutes.  
Gels were stained with coomassie dye solution (50% methanol, 10% acetic acid, 1gm/L 
coomassie blue G250) and de-stained with a methanol/acetic acid solution (50% 
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methanol, 10% acetic acid). Gels were subsequently dried using a gel drying system 
(DryEase Minigel Drying System, Invitrogen).  The stained, dried gels were then exposed 
for 48 hours on phosphor screen (Molecular Dynamics) to identify the radiolabeled 
selenoprotein bands.  Image analysis was performed using Image Quant software 
(Molecular Dynamics).   
 
Western Blot Analysis of Protein Levels 
 Equal protein amounts were separated with 12% SDS PAGE as described in the 
previous section.  Following electrophoresis, the gels were removed from the glass plates, 
soaked in transfer buffer (25 mM Tris, 80 mM glycine, 20% methanol) and placed in a 
transfer cassette with PVDF membrane (Bio-Rad).  The PVDF membrane was pre-wet 
with ethanol, and then soaked for at least five minutes in the transfer buffer, and then 
assembled with the gel as described by the manufacturer (Bio-Rad). Proteins were 
transferred to PVDF at a constant voltage (100 volts).  Following the transfer, the 
membrane was removed from the transfer cassette and incubated with blocking solution 
(TBS with .01% Tween 20 containing 2% BSA) for 1 hour at room temperature.  Once 
blocked, the membrane was incubated with the primary antibody (rabbit anti-human 
thioredoxin reductase- gift of T.C. Stadtman) at a 1:500 dilution made in blocking 
solution overnight at 4°C.  Following incubation with the primary antibody, the 
membrane was washed 3 times for 5 minutes each wash with TBS-Tween.  The 
secondary antibody (goat anti-rabbit conjugated with alkaline phosphatase) was diluted 
1:2,500 in blocking solution and was incubated with the membrane for one hour at room 
temperature.  After one hour, the secondary antibody was removed by three subsequent 
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washes with TBS-Tween, and then rinsed briefly in alkaline phosphatase buffer (0.1M 
Tris, 100mM NaCl, 5mM MgCl,  pH 9.5).  The alkaline phosphatase substrate was 
dissolved in 10 mL of alkaline phosphate buffer and contained 0.34 mL 5-bromo, 4-
chloro, 3-indolyl phosphate (BCIP) and 0.67 mL of nitroblue tetrazolium (NBT).  The 
membrane was incubated with substrate until the product was visibly detectable. The 
reaction was then stopped by washing with dH20 and allowed to dry. 
 
UV Irradiation Studies 
HaCaT cells were cultured in 12- well dishes (TPP) and 96 well dishes (TPP) for 
UV studies. A Rayonet Photochemical Reactor was used with broadband UVA-UVB 
bulbs with a peak emission at 305 nm.  The UV reactor was the gift of Dr. Belfield 
(University of Central Florida- Department of Chemistry).  The reactor was turned on at 
least 20 minutes before treating cells to allow bulbs to warm up. An internal fan was also 
used inside the UV reactor to ensure the proper temperature was maintained (35 degrees) 
and this was verified using a thermometer.  A radiometer/photometer (International 
Light) was used to detect the UV irradiance from the lamps before treatment of the cells. 
Before treatment with UV, cell medium was removed and set aside in sterile tubes. Cells 
were covered with PBS containing calcium and magnesium (Cellgro).  One mL of PBS 
was used for cells in 12-well dishes, and 50µL of PBS was used for cells in 96-well 
dishes. Cells which were not being irradiated were protected from UV light by covering 
wells with several layers of aluminum foil (Fisher Scientific).  Following UV irradiation 
of cells, original culture media was replaced, and cells were returned to incubator. 
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 UV Induced Cytotoxicity Studies.  HaCaT cells were cultured in 24 well dishes 
in media that consisted of 90% defined keratinocyte media (DKM) and 10% DMEM. The 
HaCaT cells underwent a gradual transition to this media by increasing the percentage of 
DKM and decreasing the percentage of DMEM (with 10% serum) with each passage of 
the cells. The first passage of cells was done performed in media that consisted of 25% 
DKM and 75% DMEM. The next passage of the cells was performed in a 50% mixture of 
each type of medium, and so on. An attempt was made at transitioning cells to 100% 
DKM,  however these cells did not recover well from this transition and were very slow 
growing. It was therefore determined that the optimal ratio of defined media with DMEM 
was 90% DKM and 10% DMEM with serum.  Thus the final concentration of FCS was 
1%.  
 Cells gradually transitioned to 90% DKM and 10% DMEM with serum (hereafter 
termed 90:10) were plated in 24-well plates at a density of 48,400 cells per well. Twenty 
four hours following the initial plating, the media was exchanged for fresh 90:10 media. 
Fresh dilutions of the LASe were prepared in 95% ethanol. The LASe was added to the 
cells in the following concentrations: 10 nM, 25 nM, 50 nM, 100 nM, 500 nM.  Twenty 
four hours after the LASe was added, the media was pooled for each concentration and 
set aside. Each well was covered with 500 µL of PBS containing calcium and 
magnesium. The cells were then UV irradiated with a dose of UVA/UVB of 500 J/m2, 
750 J/m2, 1000J/ m2.  The pooled media was then replaced and the cells were returned to 
the incubator. A control was also performed in which the media was pooled and set aside 
and the cells were covered with 500 µL of PBS containing calcium and magnesium and 
set in the dark for one minute. Media was then replaced in the control cells and they were 
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returned to the incubator.  Forty eight hours after UV irradiation, cell viability was 
assessed using the MTT assay. 
Toxicity of LASe Compared to Other Selenium Compounds.  Cells were 
cultured in 96 well dishes in 90:10 and approximately 2,100 cells per well were initially 
plated.  Following a 24 hour incubation, to allow cells to adhere as a monolayer, 
approximately 5,000 cells per well are expected based on cell viability assessed using 
Trypan Blue (see previous section). After 24 hours of incubation, medium was removed 
and replaced with fresh medium. At this time, LASe, L- selenocysteine, and selenite were 
added to the cells in triplicate in the following concentrations 1 µM, 5 µM, 10 µM, 15 
µM, 25 µM, with the appropriate control (0 µM selenium compound).  After incubation 
for twenty four hours, cell viability was assessed using MTT assay.  
 Ethanol Toxicity.  HaCaT cells were plated in 24-well plates (TPP) at 48,400 
cells per well.  This number was chosen because this is proportionate to the amount of 
cells plated in a 96-well plate in other analysis. The ratio of the increased amount of 
media added to the 12-well plates compared to the 96-well plates would be the ratio to 
use in determining the amount of cells to plate. Cells were initially plated in 1mL of 
DMEM, media was exchanged 24 hours after plating, and 95% ethanol was added in the 
following percentages: 0.25%, 0.35%, 0.5%, 0.75%, 1.0%, and 2.0%.  Cell viability was 
assessed by MTT assay as described above, with adaptations made in the volumes of 
reagents used so that the amounts would be proportional to the amounts used in 96 well 
plates. Instead of 10µL of MTT solution, 100µL was used. Similarly, 1mL of the SDS-
HCl solution was used instead of 100µL.  Aliquots (200uL) were then transferred to 96-
 29
well plates and the absorbance at 570nm was determined using the microplate reader, as 
previously described. 
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CHAPTER 3: RESULTS 
 
Nutritional Utilization in HeLa Cells 
To determine whether or not the selenium derived from LASe would be utilized 
efficiently for selenoprotein synthesis in mammalian cells, we first used a cell line that is 
well established, HeLa S3.   To allow for cell proliferation, and, in turn, significant 
protein synthesis, cells were cultivated to 60% confluence and then labeled with 75Se. At 
the same time unlabeled selenium compounds were added to the cells in increasing 
concentrations.  Unlabeled LASe, L-selenocysteine, and selenite were added in 
concentrations from 25nM to 150nM. These experiments were carried out in order to 
compare the nutritional utilization of the selenium in LASe to the utilization of two other 
well-studied and efficient forms of selenium.  In addition to the low concentrations 
(25nM-150nM), LASe was added to labeled cells in higher concentrations. The range for 
this study was from 250nM-1µM. Unlabeled L-selenomethionine and selenate were also 
added to labeled cells in the same concentrations. This experiment was carried out to 
assess the utilization of the compound when supplied to cells in a higher dose, as well as 
to compare its utilization to the 2 other well-studied selenium compounds. A much higher 
dose was required for such a comparison, as L-selenomethionine and selenate are not 
utilized with as high efficiency as L-selenocysteine and selenite for specific selenoprotein 
biosynthesis.  Cells were cultured for 48 hours after the compounds were added to allow 
sufficient time for new selenoprotein synthesis and labeling. 
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As shown in Figure 4, radiolabeling experiments in HeLa reveal that unlabeled 
selenium in the form of LASe, L-selenocysteine , and selenite are efficiently utilized for 
selenoprotein synthesis. This experiment assumes that the 75Se comes from radiolabeled 
selenium which was incorporated during selenoprotein synthesis, as culture medium was 
removed before harvesting cells, and cells were lysed prior to analysis of protein and 75Se 
content. 
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Figure 4 
Efficiency of Utilization of LASe, L-SeCys and Selenite in HeLa Cells. Radiolabeled 
selenoprotein levels were determined in extract of HeLa cells treated with concentrations 
of selenium compounds from 25nM-150nM and labeled with with  75Se.  Data represent 
the average of at least three separate cultures with standard deviation shown as the error.  
The cells were incubated with compounds for 48 hours. 
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Because L-selenocysteine and selenite are both very efficient as nutritional sources of 
selenium in mammalian cells, these unlabeled selenium compounds readily compete with 
75Se in the form of selenite in the cells.  LASe is able to compete with the 75Se in the 
cells, as an upward trend is also seen in the 75Se efficieny of utilization with  increasing 
concentrations of the compound, though the effect is not as dramatic as that seen with 
addition of L-selenocysteine and selenite. In Figure 5, the decreased radiolabeling effect 
is shown for a specific selenoprotein, thioredoxin reductase (indicated by arrow).   
 
LASe L-SeCys con 
25   50    100   150   25    50    100 150  0nM 
Figure 5 
Autoradiography of a Representative SDS-PAGE of Cell Extracts from HeLa Cells 
Treated with LASe and L-SeCys. 15 µg of protein was loaded in each lane. Arrow 
shows the band representing thioredoxin reductase, the most abundant selenoenzyme in 
keratinocytes. 
 
Utilization of LASe and L-selenocysteine are compared side- by -side in this 
representative figure.  Triplicate experiments with cells treated with all three compounds 
in the four concentrations (25nM-150nM) were performed, with results similar to those 
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shown in the representative gel shown above. Decreased selenoprotein radiolabeleing 
with increasing concentrations of unlabeled LASe and L-selenocysteine is seen following 
SDS-PAGE analysis of cellular proteins from treated HeLa cell extracts and 
autoradiography of the gel.   
 Quantification of the labeled thioredoxin reductase band from the gels was 
performed using Image Quant analysis and correlated directly with the analysis of total 
isotope incorporation (data not shown).  The amount of 75Se present in the thioredoxin 
reductase from the cell extract decreased with increasing concentrations of all three 
selenium compounds.  LASe was shown to compare well with the other two forms of 
selenium in terms of its ability to be incorporated into thioredoxin reductase in this 
analysis.  Since the data for the 75Se counts per µg of protein and the quantification of 
radiolabeled thioredoxin reductase are similar, one may assume that the 75Se counts per 
µg of protein corresponds to the  specific 75Se radiolabeling of selenoenzymes.  
Two forms of selenium which are present in most nutritional supplements of 
selenium due to their low toxicity are selenomethionine and selenate. Comparing the 
nutritional availability of the selenium in LASe to these two selenium compounds that are 
commonly used as supplements, LASe was shown to be a more efficient source of 
selenium for selenoprotein synthesis.  As seen in figure 6, when HeLa cells were treated 
with the same concentrations of LASe, selenomethionine, and selenate, selenium from 
LASe was most effective as a nutritional source of selenium.   
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Figure 6 
Incorporation of Selenium from LASe, L-SeMet and Selenate into Selenoproteins.  
HeLa cells were cultured in the presence of selenium compounds and were labeled with 
75 Se (selenite, 10 nM) as in figure 4.  
 
Figure 7 shows that the selenium from the unlabeled selenium compounds is 
being efficiently utilized by the cells, as it is incorporated into selenoproteins.  In 
particular, the autoradiography demonstrates that the cells can rapidly utilize the selenium 
from the unlabeled selenium compounds for synthesis of the 60 kDa selenoprotein 
thioredoxin reductase (indicated with arrow) at different efficiencies.  Selenium supplied 
from LASe was a better nutritional source than selenium supplied from either L-
selenomethionine or selenate.  Consequently, selenium from LASe is more efficient as a 
nutritional source of the micronutrient than these forms in a HeLa cell culture model. 
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con  LASe       L-SeMet                                     con selenate 
0  250  500   750 1000   250 500 750  1000nM                                         0      250 500 750 1000nM 
Figure 7 
Representative SDS-PAGE to Compare Efficiency of Selenium Incorporation into 
HeLa Cell Extracts Treated with LASe, L-SeMet and Selenate. TrxR (arrow) 
decreases as increasing concentrations of unlabeled selenium compounds are 
incorporated into selenoproteins. Cells were cultured in the presence of Se compounds 
(250nM-1µM) for 48 hours. 20 µg of protein was loaded in each lane. 
 
Overall Protein Levels in HeLa Cells do not Decrease  
  
To confirm that the changes seen in the levels of radiolabeled selenoproteins were 
not due to an overall decrease in selenoprotein synthesis, the protein levels of the 
cytosolic TrxR were determined by a Western blot. Thioredoxin reductase was chosen as 
the specific selenoprotein to probe for, as it is the most abundant selenoprotein in HeLa 
cells. As shown in figure 8, the bands corresponding to thioredoxin reductase in cell 
extracts treated with all concentrations of selenate are of similar intensity. This 
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demonstrates that thioredoxin reductase was continiuously synthesized at a similar level 
in the cells treated with selenate in increasing concentrations.  The cells were utilizing the 
unlabeled selenate as a source of selenium for synthesis of new thioredoxin reductase 
(figure 8).   
 
 
 
con       selenate 
0             250             500         750            1000nM 
Figure 8 
Western Blot Detecting Thioredoxin Reductase in HeLa Cells Treated with 
Increasing Concentrations of Selenate. 
 
Similar results were obtained in cells treated with selenate is seen in those treated with 
LASe and L-selenomethionine. This is summarized in figure 9, as the level of thioredoxin 
reductase detected by immunoblot in cells treated with LASe and L-selenomethionine 
remains constant.  
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Figure 9 
Western Blot to Detect Thioredoxin Reductase in HeLa Cells Treated with LASe 
and L-SeMet. 
 
These results confirm the assumption that changes in the radiolabeling of selenoproteins 
were reflecting only the incorporation of unlabeled selenium from the compound of 
interest in the experiment. 
 
Nutritional Utilization in HaCaT Keratinocytes 
 Following upon the results from the HeLa cell model, we decided to test the 
LASe compound in a second mammalian cell line to determine if similar results would be 
obtained and to test a cell type that is relevant for topical skin use of LASe.  Due to the 
ease with which this compound crosses hydrophobic barriers, such as skin (unpublished 
data) we chose the skin cell line HaCaT.  This is a spontaneously transformed 
keratinocyte cell line which is widely used in studies requiring a skin cell model.  The 
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method for determining utilization of the compound for selenoprotein synthesis in HaCaT 
cells was the same as that used with HeLa S3 cells. Cells at approximately 60% 
confluence were treated with 75Se, and at the same time increasing concentrations of 
unlabeled selenium compounds were added. For the comparison of more efficiently 
utilized selenium forms, LASe, L-selenocysteine, and selenite were added to the cells in 
concentrations from 25nM to 200nM.  To compare LASe utilization in HaCaT to the less 
efficiently utilized selenium compounds L-selenomethionine and selenate, LASe, L-
selenomethionine, and selenate were added to the cells in concentrations from 200nM to 
1µM. 
  The nutritional utilization of the compounds in HaCaT cells is shown in figures 
10 and 11.  Similar to results from experiments in HeLa cells there was good utilization 
of selenium from LASe for selenoprotein synthesis.   
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Figure 10 
Incorporation of Selenium from LASe, L-SeCys, and Selenite in HaCaT.  HaCaT 
cells were cultured in the presence of selenium compounds and were labeled with 75Se 
(selenite 10nM). 
 
In fact, it appears that the selenium in LASe is used more efficiently in HaCaT cells when 
supplied in low dosages, than in HeLa cells when it was supplied in similar dosages 
(figure 4).  It appears that in HaCaT the selenium from LASe is utilized with nearly the 
same efficiency as selenocysteine, and with higher efficiency than selenite.  As shown in 
figure 10, the data from the radiolabeling of cell protein in treated HaCaT (figure 11) 
corresponds to the radiolabeling of thioredoxin reductase in this representative 
autoradiography of a gel run with treated HaCaT cell extracts. 
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 con LASe                  SeCys                                    selenite 
    0   25   50  100 150  25  50 100 200nM                 25  50  100 200nM 
Figure 11 
Autoradiography of  SDS-PAGE Separating Extracts of HaCaT Cells Treated with  
25nM-200nM Unlabeled Se Compounds and Labeled with 75 Se. 40µg of cell protein 
was loaded in each well. Arrow indicates TrxR. 
 
As with the HeLa cells, the ability of HaCaT cells to utilize the selenium from LASe 
when supplied in higher dosages was compared to the less efficiently utilized forms of 
selenium, selenomethionine and selenate.  Figure 11 shows the efficient incorporation of 
LASe into selenoproteins.  
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Figure 12 
Incorporation of Selenium from LASe, L-SeMet, and Selenate in HaCaT.  HaCaT 
cells were cultured in the presence of selenium compounds and were labeled with 75Se 
(selenite 10nM). 
 
Autoradiography of cell extracts separated by SDS-PAGE and treated with LASe, L-
SeMet and selenate demonstrates that the selenium from the compounds was utilized for 
synthesis of selenoproteins (figure 13).   
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 LASe                L-SeMet                                         con  selenate 
250 500 750 1000    250 500 750 1000nM                          0       250 500 750 1000nM 
Figure 13 
Autoradiography of Cell Extracts Separated by SDS-PAGE of HaCaT Cells Treated 
with 250 nM- 1µM Unlabeled Se Compounds and Radiolabeled with 75 Se.  100µg of 
cell protein was loaded in each well. Arrow indicates TrxR. 
 
 
Toxicity of LASe in HaCaT /Comparison to other selenium compounds 
 The first experiment performed to compare the toxicity of LASe in HaCaT cells 
was performed in 96-well microplate.  The results for both selenite and L-SeCys are 
similar in the effect that 1µM of each had on the cells. It appears as if this addition of 
selenium has a growth enhancing effect on the cells, as the amount of viable cells (by 
MTT assay) at 24 hours after treatment with both compounds in 1µM concentrations is 
about 20-30% higher than the untreated (control) cells. As the concentration of selenium, 
in the form of selenite and L-selenocysteine increases, there is gradual decrease in cell 
viability at 24 hours after treatment. 
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Figure 14 
Toxicity of L-SeCys in HaCaT. 
Graph represents cell viability (compared to control) assessed by MTT assay 48 hours 
after pretreatment with selenocysteine in various concentrations.  Each bar is the result of 
at least 3 independent cultures, with standard deviation plotted as the error. 
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Selenite Toxicity in HaCaT Keratinocytes
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Figure 15. 
Toxicity of Selenite in HaCaT 
Graph represents cell viability 48 hours after treatment with increasing concentrations of 
selenite, assayed for by MTT reduction.  Each bar is the result of at least 3 independent 
cultures, with standard deviation plotted as error. 
 
 
 After adding LASe to the cells in the same way in which selenite and L-SeCys 
were added, a different set of results was obtained. The initial addition of LASe in 
concentrations above 1µM had a negative effect on the viability of the cells, as 
determined by the MTT assay. Moreover, the negative effect that the LASe compound 
had was much more dramatic than the effect of the other two compounds.  Because the 
nutritional studies with this compound have shown that it is utilized with nearly the same 
efficiency as selenite and selenocysteine, we did not expect that LASe itself would be 
more toxic than the other selenium forms being tested. To further investigate this effect, 
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we decided to test the toxicity of ethanol in HaCaT cell culture since this was the solvent 
added to the cells with LASe. The LASe is eluted in ethanol from the HPLC, and 
dilutions from the stock solution of LASe are made in 95% ethanol as well. In 96 well 
plates, cells are grown in 100µL of medium. The addition of just one microliter of the 
diluted LASe compound adds ethanol in a concentration that is equal to 1% of the total 
volume of the cell’s medium.  To determine if the ethanol, not the LASe was having a 
negative effect on cell viability, we added ethanol by itself in concentrations ranging 
from 0.25%-2.0%, and assessed the viability of the cells by measuring the reduction of 
MTT 24 hours after treatment. Based on the results of the MTT assay, we can assume 
that the ethanol was toxic to the cells and that only up to 0.5% ethanol in the total culture 
medium is safe to add to the cells.  The addition of ethanol in concentrations higher than 
0.5% of the total culture medium appears to have a negative effect on cell viability, as 
assayed by MTT reduction. 
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Ethanol Toxicity in HaCaT
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Figure 16 
Ethanol Toxicity in HaCaT 
Graph represents the cell viability 48 hours after pretreatment with ethanol in 
concentrations from 0.1%-2.0%.  Each bar is the result of 3 independent cultures, with 
standard deviation plotted as the error. 
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Figure 17 
Toxicity of LASe (diluted into 5% ethanol) in HaCaT 
Graph shows cell viability following pretreatnment with various concentrations of LASe . 
The final dilutions of LASe were made into 5% ethanol.  Each bar is the result of three 
independent cultures, with standard deviation plotted as the error. 
 
Once LASe was added to cells after being diluted in 5% ethanol, it was evident 
that LASe itself was not toxic to the cells. In fact, because these cells were deficient in 
selenium, due to their continuous culture in 90% defined media and 10% DMEM 
supplemented with serum, the addition of the selenium had a slight proliferative effect, 
indicated by an increase in MTT reduction.  To determine if perhaps the lipoic acid 
component of the LASe were toxic to the cells, LA alone was diluted in 5% ethanol and 
added to the cells. The results are shown in figure 18. 
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Figure 18 
Toxicity of LA in HaCaT 
The graph shows the % of cells alive after being pre-treated with lipoic acid at various 
concentrations. Each bar is the result of three independent cultures, with standard 
deviation plotted as the error. 
 48
 
It is clear LA, like LASe is not toxic to HaCaT cells. Furthermore, the same proliferative 
effect seen in the cells pretreated with LASe was seen in cells treated with LA. According 
to our studies, selenite is not toxic in concentrations up to 2 µM (figure 15). Taken 
together, this indicates that LASe and its individual components are not toxic to HaCaT 
cell in sub-micromolar concentrations.  Thus, we began testing LASe in sub-micromolar 
concentrations to determine whether it could protect cells from UV induced cytotoxicity. 
 
 
 
UV Irradiation of HaCaT Cells 
Before moving to studies involving the ability of selenium compounds to protect 
HaCaT cells from UV induced cell death, it was first necessary to determine the correct 
range of UV light to expose the cell to in order to induce cell death as a measurable 
endpoint. To determine the amount of UV necessary to cause cytotoxicity, cells were 
cultured in 12-well dishes until approximately 80% confluent.  Cells were irradiated as 
described, and then incubated for 24 hours before assessing cytotoxicity by counting cells 
using trypan blue dye exclusion with a hemocytometer. Approximately 70% of the cells 
were killed with 750J/m2 of broadband UV irradiation, 50% with 500J/ m2, 18% with 
250J/m2.  Figure 19 summarizes the changes in of cell viability 24 hours after UV 
irradiation, compared to untreated cells, 24 hours after UV irradiation.   
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 Broadband UV Irradiated HaCaT Cells
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Figure 19 
Cell Viability Following UV Irradiation, Determined by Trypan Blue Exclusion  
Graph represents the percentage of cells, compared to untreated cultures viable 24 hours 
after UV irradiation.  Each bar represents the average of three independent cultures, with 
the standard deviation plotted as the error. 
 
In addition to cultivating cells in the 12 well dishes and determining the effective 
UV dosage to kill the cells using trypan blue staining and cell counting using a 
hemocytometer, cells were also cultured in 96-well plates and cell death was assessed by 
MTT assay. This was carried out to establish the UV dosage required to kill 
approximately 80% of the cells in these plates.  This UV dosage, once established would 
be used for future protection studies. Cells were exposed to 100J/m2, 250J/m2, 500J/m2, 
750J/m2 and 1000J/m2 of broadband UVA-UVB light.  As summarized in figure 20, 
similar results were obtained in the 96 well plates when the viability of cells was assayed 
for using MTT.  This validates the use of MTT to assess cell viability upon UV exposure 
to keratinocytes. 
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Effect of UV on Viability of HaCaT Cells
UV dosage
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Figure 20 
Cell Viability Following UV Irradiation, Determined by MTT Assay 
Graph represents cell viability 48 hours after UV irradiation with dosages ranging from 
100J/m2-10000J/m2.  Each bar represents at least 3 independent cultures, with the 
standard deviation plotted as the error. 
 
 
Determination of lethal UV dose for HaCaT cells cultured in 90% defined media and 
10% DMEM 
 Since serum contains selenoprotein P and undefined forms of selenium, we chose 
to carry out experiments defined keratinocyte media (36). This modified DKM contains 
1% serum (as defined in the methods section 90:10), which reduces the presence of other 
forms of selenium which are present in serum.  Cells grown in 90:10 media, then, have 
only one predominant form and amount of selenium available to them, 7nM selenite.  The 
comparison studies performed in this media are much more representative of the effects 
of compounds which are added to the cells, than if they were added to cells cultured in  
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DMEM with 10% serum.   To confirm that the UV dosage effective to result in 
cytotoxicity of  HaCaT cells cultured in 90% DKM and 10% DMEM, cells were treated 
with varying doses of UV in the same manner as in figure 20.   
UV Sensitivity of HaCaT cultured in DKM/DMEM
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Figure 21 
Cell Viability of HaCaT in 90%DKM and 10% DMEM following UV Irradiation 
The graph represents cell viability 48 hours after UV irradiation with increasing doses of 
UV. Cells were cultured in 90% DKM and 10% DMEM (final conc. of serum 1%). Each 
bar represents at least 3 independent cultures, with the standard deviation plotted as the 
error. 
 
 
 Cells cultured in 90:10 displayed similar susceptibility to UV irradiation. Further UV 
studies were carried out using cells that had acclimated to the 90:10 media for several 
more passages. These cells exhibited nearly the same response to UV as those cultured in 
DMEM with 10% FCS. A UV dose of (figure 20) 750J/m2 resulted in a decrease in cell 
viability by approximately 80%, and a dose of 500J/m2 resulted in nearly 60% cell 
reduction in cell viability.  
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Protection of HaCaT Cells From UV Induced Cell Death 
     HaCaT cells pretreated for 24 hours with LASe as well as lipoic acid and selenite for 
comparison, were protected from UVA/UVB induced cell death. The 24 hour incubation 
period was selected in order to give the cells adequate time to metabolize the selenium 
and incorporate it into selenoproteins. The protective effect is represented in the figures 
below.  Though the cells were treated with a range of UV (250J/m2-1000J/m2), the 
protective effect of the compounds was more dramatic at higher UV dosages (500J/m2 
and 750 J/m2).  Furthermore, this effect was concentration dependent, as there was a 
gradual increase in protection observed with increasing concentrations of the compounds.  
This increase in protection eventually reached a maximum value and protection was not 
as great for cells to which higher concentrations of compounds were supplied.  
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Cell Viability 48 hours after UV irradiation with 500J/m2 
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Figure 22 
Cell Viability 48 Hours After UV Irradiation with 500J/m2 Following Pretreatment 
with LASe  
Graph represents the percentage of HaCaT cells alive 48 hours after being irradiated with 
500J/m2 of UVA-UVB.  Cells were pretreated with increasing concentrations of LASe.  
Each bar represents at least 3 independent cultures, with the standard deviation plotted as 
error. 
 
 
As represented in figure 22, LASe treatment before UV irradiation is protective.  HaCaT 
show an increase in cell viability when exposed to 500J/m2 when LASe has been supplied 
in concentrations from 25nM-500nM.  The greatest amount of protection was achieved 
when LASe was supplied at a concentration of 250nM.  The protection observed 
following pretreatment with this dose was an approximately 15% increase in cell 
viability.
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Cell Viability 48 hours after UV irradiation with 500 J/m2 
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Figure 23 
Cell Viability 48 Hours After UV Irradiation with 500J/m2 Following Pretreatment 
with Selenite 
Graph represents the percentage of HaCaT cells alive 48 hours after being irradiated with 
500J/m2 of UVA-UVB.  Cells were pretreated with increasing concentrations of selenite.  
Each bar represents at least 3 independent cultures, with the standard deviation plotted as 
error. 
 
 
Figure 23 represents the protection achieved when HaCaT were pretreated with selenite.  
In this instance, the concentration of selenite which offered the greatest amount of 
protection from UV irradiation with 500J/m2 was 25nM.  Pretreatment with 25nM 
selenite resulted in an approximate 10% increase in cell viability. 
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Figure 24 
Cell Viability 48 Hours After UV Irradiation with 500J/m2 Following Pretreatment 
with LA 
Graph represents the percentage of HaCaT cells alive 48 hours after being irradiated with 
750J/m2 of UVA-UVB.  Cells were pretreated with increasing concentrations of LA.  
Each bar represents at least 3 independent cultures, with the standard deviation plotted as 
error. 
 
   Figures 24 demonstrates that pretreatment with lipoic acid also offers protection 
from UV induced cytotoxicity.  Pretreatement with 50nM lipoic acid offered the greatest 
protection. The increase in cell viability in HaCaT treated with lipoic acid was 
approximately 15% above control values. 
 Cells were also UV irradiated with 750J/m2.  As could be expected, cell death of 
UV treated cells was higher compared to the cells not treated with UV.  As in the cells 
treated with 500J/ m2 of UV, protection from cell death by selenium compounds as well 
as LA was observed.  In the cells treated with higher UV dosage, the greatest protective 
effect observed was from pretreatment with 25nM of all of the compounds.  
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Figure 25 
Cell Viability 48 Hours After UV Irradiation with 750J/m2 Following Pretreatment 
with LASe 
Graph represents the percentage of HaCaT cells alive 48 hours after being irradiated with 
750J/m2 of UVA-UVB.  Cells were pretreated with increasing concentrations of LASe.  
Each bar represents at least 3 independent cultures, with the standard deviation plotted as 
error. 
 
 
Figure 25 summarizes the protection achieved when HaCaT were pretreated with LASe 
and irradiated with a high dose of UV (750J/m2).  There was a dose dependent response 
to the level of protection offered by LASe, with the greatest protection achieved when 
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LASe was supplied at 25nM.  At this dose of LASe, there was an approximate 21% 
increase in cell viability as compared to the control values.   
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Figure 26 
Cell Viability 48 Hours After UV Irradiation with 750J/m2 Following Pretreatment 
with Selenite 
Graph represents the percentage of HaCaT cells alive 48 hours after being irradiated with 
750J/m2 of UVA-UVB.  Cells were pretreated with increasing concentrations of Selenite.  
Each bar represents at least 3 independent cultures, with the standard deviation plotted as 
error. 
 
 
 58
As presented in figure 26, 25nM selenite was the dose which offered the highest 
protection for cells irradiated at 750J/m2.  This is the same dose of LASe which had 
provided the highest level of protection from the same UV irradiance.  Likewise, the level 
of protection was nearly the same (21% increase in cell viability). 
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Figure 27 
Cell Viability 48 Hours After UV Irradiation with 750J/m2 Following Pretreatment 
with LA 
Graph represents the percentage of HaCaT cells alive 48 hours after being irradiated with 
750J/m2 of UVA-UVB.  Cells were pretreated with increasing concentrations of LA.  
Each bar represents at least 3 independent cultures, with the standard deviation plotted as 
error. 
 
 
Similar results were observed regarding the level of protection offered by lipoic acid as in 
the studies examining LASe and selenite at 750J/m2.  Lipoic acid supplied at 25nM 
offered the greatest protection from UV, and the protection observed was also a 21% 
increase in cell viability upon pretreatment.
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 CHAPTER 4: DISCUSSION 
 
This study has demonstrated the potential of a novel selenium compound (LASe) 
to provide selenium as a nutritional source and to protect skin cells in culture from UV 
induced cell death.  Since the selenium from LASe was efficiently utilized for 
selenoprotein synthesis it has potential as a nutritional supplement   The protective effect 
of the compound in the UV protection experiments, then, is likely due to its ability to 
increase the level of antioxidant enzymes such as glutathione peroxidase and thioredoxin 
reductase. The radiolabeling competition studies demonstrated that LASe was more 
efficient than selenomethionine and selenate, especially in the target cell line, HaCaT. 
This finding is significant, as selenomethionine is a commonly used form of selenium as 
a supplement.  Because selenomethionine has the potential to be non-specifically 
incorporated into methionine residues of proteins, its use as a supplement may not be 
ideal.  In addition to demonstrating far greater efficiency than selenomethionine and 
selenate, LASe compared well with the two most efficient forms of selenium, selenite 
and selenocysteine. This nutritional evidence indicates that LASe has the potential for use 
as a supplement.  
 To more accurately study the effects of LASe in cell culture, a defined medium 
was used for protection studies. This medium eliminated most of the serum present in 
standard DMEM culture medium, which was necessary for these studies, as serum 
contains a number of different selenium sources, including selenoprotein P and one form 
of Gpx, as well as a small molecule form of selenium that has yet to be identified. 
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Consequently, the effects of the selenium compounds in this study could be studied 
individually, without the presence of unknown forms. Protection studies performed by 
other groups examining protection by selenium compounds other than LASe in cell 
culture were done in standard culture medium (DMEM).  
The protective effect of LASe was comparable to the effect shown by its 
individual components, lipoic acid and selenite.  This was not expected, since selenite is a 
good nutritional form of selenium and lipoic acid has been shown to be a potent 
antioxidant. The expected result would have been protection by LASe which was more 
than that achieved by selenite or lipoic acid treatment alone, however, this synergistic 
effect was not observed.  The graphs representing the protection of HaCaT from 750J/m2 
most clearly show the protection from these compounds, and indicate that the protective 
effect is dose dependent. It appears that when HaCaT are pretreated with lipoic acid, 
selenite and LASe, the common dosage offering the greatest amount of protection is 
25nM.  The amount of protection offered by the three compounds was very similar and 
resulted in approximately a 21% increase in cell survival following UV irradiation. The 
graphs of the protection observed at 500J/m2 resemble the graphs in the toxicity study. 
Consequently, the proliferative effect observed following the addition of these 
antioxidant compounds to slightly stressed cells in culture (due to elimination of serum 
from medium) is evident in cells treated with lower dosages of UV.  There is, however, a 
protective effect observed at the lower dosage (500J/m2) of UV as well as higher (750J/ 
m2) dosage.  
The fact that LASe is not toxic to cells in culture at concentrations up to one 
micromolar is significant. Furthermore, it has been demonstrated that LASe offers 
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protection to skin cells in culture from UV induced cell death. Combined with the 
evidence that this compound is absorbed into skin, it presents itself as a possible topical 
supplement which can offer protection from UV generated oxidative stress.  To further 
investigate the mechanism by which LASe is protective of UV induced cytotoxixity, we 
would like to determine if supplementation results in increased activity of TrxR and Gpx.  
Furthermore, we would like to determine if any increase in the levels of these antioxidant 
enzymes correlates with increased UV protection.  In addition, we would like examine 
any protection that this compound may offer from specific forms of oxidative stress, such 
as protein carbonylation and production of peroxides.  Finally, our goal is to move our 
studies involving LASe’s UV protective ability from cell culture models to an animal 
model. 
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